谷红注射液联合丹参多酚酸盐对急性脑梗死患者神经功能和血液流变学的影响

doi:10.3969/j.issn.1004-583X.2021.03.004

摘要/Abstract

摘要：

目的探讨谷红注射液联合丹参多酚酸盐对患者神经功能和血液流变学的影响。方法选择我院收治的急性脑梗死患者154例,根据随机数字表法分为对照组77例,采用丹参多酚酸盐治疗;联合组77例,采用丹参多酚酸盐联合谷红注射液治疗。比较两组临床疗效、神经功能缺损程度评分、血液流变学指标,观察治疗期间不良反应发生情况。结果治疗后,联合组总有效率高于对照组(P<0.05);两组神经功能缺损程度评分均较治疗前下降,且联合组低于对照组(P<0.05)。两组血浆黏度、全血高切黏度、全血低切黏度、纤维蛋白原水平均较治疗前下降,且联合组低于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论谷红注射液联合丹参多酚酸盐治疗急性脑梗死,可有效改善患者神经功能缺损和血液流变学,疗效显著,且安全性较好,具有一定临床应用价值。

关键词: 脑梗死, 谷红注射液, 丹参多酚酸盐, 神经功能, 血液流变学

Abstract:

Objective To investigate the effect of Guhong injection combined with salvianolate on neurological function and hemorheology in patients with acute cerebral infarction(ACI). Methods A total of 154 ACI patients in our hospital were selected as the research objects, and were divided into control group (77 cases,treated with salvianolate) and combined group (77 cases,treated with salvianolate combined with Guhong injection) by the random list method. The clinical efficacy, defect score of nervous function and hemorheology indexes were compared in the two groups, and the occurrence of adverse reactions was observed during the treatment. Results After treatment, the total effective rate of the combined group was higher than that of the control group (P<0.05). The neurological deficit scores of the two groups were lower than those before treatment, and the combined group was lower than the control group (P<0.05). The plasma viscosity, whole blood high shear viscosity, whole blood low shear viscosity, fibrinogen level of the two groups were decreased than that before treatment, and the score of the combined group was lower than that of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion The neurologic impairment and hemorheology of ACI patients can effectively improve by Guhong injection combined with salvianolate, being significant curative effect and good safety, and has certain clinical application value.

Key words: brain infarction, guhong injection, salvianolate, neurological function, hemorheology

中图分类号:

R743.33

赵杨, 马良, 钟启刚. 谷红注射液联合丹参多酚酸盐对急性脑梗死患者神经功能和血液流变学的影响[J]. 临床荟萃, 2021, 36(3): 212-215.

Zhao Yang, Ma Liang, Zhong Qigang. Effects of Guhong injection combined with salvianolate on neurological function and hemorheology in patients with acute cerebral infarction[J]. Clinical Focus, 2021, 36(3): 212-215.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2021.03.004

https://huicui.hebmu.edu.cn/CN/Y2021/V36/I3/212

图/表 3

参考文献 20

[1]	Sui B, Gao P. Imaging evaluation of acute ischemic stroke[J]. J Int Med Res, 2020,48(1):300060518802530.
[2]	李继红, 李琼. 影响老年急性脑梗死病人神经功能缺损程度的相关因素分析[J]. 实用老年医学, 2020,34(3):295-298.
[3]	尤晓涵, 杨淼, 明霞光, 等. 盐酸川芎嗪注射液联合丁苯酞软胶囊治疗急性脑梗死疗效及对患者血液流变学影响[J]. 陕西中医, 2020,41(6):743-745,757.
[4]	Shibata K, Hashimoto T, Miyazaki T, et al. Thrombolytic therapy for acute ischemic stroke: Past and future[J]. Curr Pharm Des, 2019,25(3):242-250. doi: 10.2174/1381612825666190319115018 URL
[5]	赵琴琴, 吕立嵩, 陈燕华, 等. 注射用丹参多酚酸盐的临床应用评价[J]. 中国基层医药, 2020,27(10):1198-1202.
[6]	中国医师协会中西医结合医师分会《谷红注射液临床应用中国专家共识》编写组. 谷红注射液临床应用中国专家共识[J]. 中西医结合心脑血管病杂志, 2020,18(11):1665-1670.
[7]	中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2014[J]. 中华神经科杂志, 2015,48(4):246-257.
[8]	Runde D. Calculated Decisions: National Institutes of Health Stroke Scale (NIHSS)[J]. Emerg Med Pract, 2019,21(Suppl 6):CD1-CD3.
[9]	郑筱萸. 中药新药临床研究指导原则:试行[M]. 北京: 中国医药科技出版社, 2002: 104.
[10]	Siri SRA, Braaten T, Jacobsen BK, et al. Distribution of risk factors for cardiovascular disease and the estimated 10-year risk of acute myocardial infarction or cerebral stroke in Sami and non-Sami populations: The SAMINOR 2 Clinical Survey[J]. Scand J Public Health, 2018,46(6):638-646. doi: 10.1177/1403494818773534 URL
[11]	Sun Z, Xu Q, Gao G, et al. Clinical observation in edaravone treatment for acute cerebral infarction[J]. Niger J Clin Pract, 2019,22(10):1324-1327. doi: 10.4103/njcp.njcp_367_18 pmid: 31607719
[12]	NanZhu Y, AiChun J, Xin L, et al. Salvianolate injection in the treatment of acute cerebral infarction: A systematic review and a meta-analysis[J]. Medicine (Baltimore), 2018,97(47):e12374. doi: 10.1097/MD.0000000000012374 URL
[13]	Kirkpatrick AC, Stoner JA, Dale GL, et al. Higher Coated-Platelet Levels in Acute Stroke are Associated with Lower Cognitive Scores at Three Months Post Infarction[J]. J Stroke Cerebrovasc Dis, 2019,28(9):2398-2406. doi: S1052-3057(19)30302-7 pmid: 31311696
[14]	Lee C, Na JU, Lee JH, et al. Characteristics of blood tests in patients with acute cerebral infarction who developed symptomatic intracranial hemorrhage after intravenous administration of recombinant tissue plasminogen activator[J]. Clin Exp Emerg Med, 2019,6(2):160-168. doi: 10.15441/ceem.18.056 URL
[15]	杨艳, 韦炎龙, 方峰. 丹参中活性成分在心血管疾病中的研究进展[J]. 中医临床研究, 2020,12(21):37-40,56.
[16]	Ling C, Liang J, Zhang C, et al. Synergistic effects of salvianolic acid b and puerarin on cerebral ischemia reperfusion injury[J]. Molecules, 2018,23(3):564. doi: 10.3390/molecules23030564 URL
[17]	Wang FJ, Wang SX, Chai LJ, et al. Xueshuantong injection (lyophilized) combined with salvianolate lyophilized injection protects against focal cerebral ischemia/reperfusion injury in rats through attenuation of oxidative stress[J]. Acta Pharmacol Sin, 2018,39(6):998-1011. doi: 10.1038/aps.2017.128 URL
[18]	何前松, 况时祥, 王少峡, 等. 丹参多酚酸对脑缺血再灌注损伤糖尿病大鼠神经功能及微管相关蛋白2表达的影响[J]. 中华行为医学与脑科学杂志, 2015,24(10):877-881.
[19]	盛飞. 谷红注射液联合奥扎格雷钠对急性脑梗死NIHSS评分、血液流变学的影响[J]. 中外医学研究, 2019,17(10):11-13.
[20]	范芳芳, 陈舒曼, 杨洪军, 等. 谷红注射液抗脑缺血网络药理学分子机制研究[J]. 复杂系统与复杂性科学, 2018,15(1):11-17.

组别	例数	基本痊愈	显著进步	进步	无效	总有效率
对照组	77	12(15.58)	39(50.65)	10(12.99)	16(20.78)	61(79.22)
联合组	77	24(31.17)	37(48.05)	11(14.29)	5(6.49)	72(93.51)
Z值						5.829
P值						0.016

组别	例数	基本痊愈	显著进步	进步	无效	总有效率
对照组	77	12(15.58)	39(50.65)	10(12.99)	16(20.78)	61(79.22)
联合组	77	24(31.17)	37(48.05)	11(14.29)	5(6.49)	72(93.51)
Z值						5.829
P值						0.016

组别	例数	治疗前	治疗后
对照组	77	14.58±3.45	9.67±3.51^a
联合组	77	15.39±3.32	5.05±3.13^a
t值		1.484	8.620
P值		0.140	<0.01

组别	例数	治疗前	治疗后
对照组	77	14.58±3.45	9.67±3.51^a
联合组	77	15.39±3.32	5.05±3.13^a
t值		1.484	8.620
P值		0.140	<0.01

组别	例数	血浆黏度(mPa·s)		全血高切黏度(mPa·s)		全血低切黏度(mPa·s)		纤维蛋白原(g·L^-1)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	77	3.35±0.46	2.48±0.23^a	13.56±0.59	7.74±1.24^a	12.65±1.86	10.84±1.25^a	4.16±1.82	2.49±0.69^a
联合组	77	3.41±0.59	1.41±0.31^a	13.49±0.54	4.59±0.93^a	12.19±1.41	7.14±1.38^a	4.49±1.97	1.21±0.56^a
t值		0.704	24.324	0.768	17.833	1.729	17.437	1.080	12.639
P值		0.483	<0.01	0.444	<0.01	0.086	<0.01	0.282	0.000